Updates enhance facility’s complete range of resources for drug product manufacturing
Halle/Westfalen, Germany, November 12, 2015 – Baxter International Inc.’s BioPharma Solutions business, a premier contract manufacturing organization (CMO) that specializes in parenteral pharmaceuticals, announced it has completed an approximately 1,800 square meter capacity expansion designed for oncology drugs at the company’s fill/finish contract manufacturing facility in Halle (Westfalen), Germany. The additional capacity reinforces BioPharma Solutions’ leadership position as one of the largest capacity CMOs for freeze-dried (lyophilized) cyto-toxic (having a toxic effect on cells) parenterals. Cytotoxic therapies like the ones manufactured at Halle continue to be at the center of oncology treatment programs.
“Cancer incidence continues to rise, and this completed expansion offers not only capacity but innovative processes and technologies that will allow Baxter to stay at the forefront of parenteral manufacturing for oncology therapies,” said Dr. Burkhard Wichert, vice president of manufacturing for Baxter’s BioPharma Solutions business. “We take seriously our commitment to world-class contract manufacturing of oncology products, and understand that the better we can serve our customers, the better they can serve patients around the world.”
The updated facility was designed by engineers with extensive experience in sterile manufacturing as an evolution of the reliable processes and equipment on-site. This includes new equipment combined with innovative disinfection systems and an optimized layout to improve efficiency, prevent contamination and keep potential losses on the filling line to a minimum. Extensive use of glass throughout the expansion area significantly improves
visibility for workers and visitors.
The ongoing development of the Halle facility is the latest in a series of recent expansions that took place in 2007 and 2011 and the addition of a new packaging line in 2013 designed to meet advanced packaging requirements of
pharmaceuticals worldwide.
“Our recent facility upgrades support early-phase drug formulation through commercial scale-up, product launch and lifecycle management,” said Dr. Wichert. “This most recent expansion will enable us to meet customers’ demands for flexibility, product quality and high yield while accommodating future needs.”
Halle/Westfalen, Germany, November 12, 2015 – Baxter International Inc.’s BioPharma Solutions business, a premier contract manufacturing organization (CMO) that specializes in parenteral pharmaceuticals, announced it has completed an approximately 1,800 square meter capacity expansion designed for oncology drugs at the company’s fill/finish contract manufacturing facility in Halle (Westfalen), Germany. The additional capacity reinforces BioPharma Solutions’ leadership position as one of the largest capacity CMOs for freeze-dried (lyophilized) cyto-toxic (having a toxic effect on cells) parenterals. Cytotoxic therapies like the ones manufactured at Halle continue to be at the center of oncology treatment programs.
“Cancer incidence continues to rise, and this completed expansion offers not only capacity but innovative processes and technologies that will allow Baxter to stay at the forefront of parenteral manufacturing for oncology therapies,” said Dr. Burkhard Wichert, vice president of manufacturing for Baxter’s BioPharma Solutions business. “We take seriously our commitment to world-class contract manufacturing of oncology products, and understand that the better we can serve our customers, the better they can serve patients around the world.”
The updated facility was designed by engineers with extensive experience in sterile manufacturing as an evolution of the reliable processes and equipment on-site. This includes new equipment combined with innovative disinfection systems and an optimized layout to improve efficiency, prevent contamination and keep potential losses on the filling line to a minimum. Extensive use of glass throughout the expansion area significantly improves
visibility for workers and visitors.
The ongoing development of the Halle facility is the latest in a series of recent expansions that took place in 2007 and 2011 and the addition of a new packaging line in 2013 designed to meet advanced packaging requirements of
pharmaceuticals worldwide.
“Our recent facility upgrades support early-phase drug formulation through commercial scale-up, product launch and lifecycle management,” said Dr. Wichert. “This most recent expansion will enable us to meet customers’ demands for flexibility, product quality and high yield while accommodating future needs.”